Tisdag 7 Juli | 14:00:35 Europe / Stockholm
Est. tid*
2027-02-16 08:30 Bokslutskommuniké 2026
2026-11-03 08:30 Kvartalsrapport 2026-Q3
2026-09-01 08:30 Kvartalsrapport 2026-Q2
2026-05-29 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2026-05-28 - Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-03-12 - Extra Bolagsstämma 2026
2026-02-16 - Bokslutskommuniké 2025
2025-11-03 - Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder bland annat en läkemedelsrobot, SaaS-lösningar och en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare globalt. iZafe Group har sitt huvudkontor i Stockholm.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

June monthly letter – strong pipeline and preparations for an intensive autumn

2026-07-07 08:45:00

June was a month in which we continued to build on the increased activity we have seen during the spring. At the same time, the upcoming holiday period is affecting the pace of certain decisions and implementations. Our focus has therefore been on driving forward the deals and start-ups that can be closed before the holidays, while also building structure and capacity ahead of an intensive autumn.

The development of active Dosell units remained positive during June, while several larger processes are now in planning, preparation and start-up after the summer. The focus is therefore on converting the strong pipeline built up during the spring into concrete implementations and more active units during the second half of the year.

Sweden – strong pipeline ahead of Q3
In Sweden, the ADDA agreement continues to create new opportunities and clearer processes for municipalities that want to introduce medication dispensers on a larger scale. During June, we have continued dialogues with several municipalities that completed their preparatory work during the spring and are now planning for call-offs and start-ups after the summer.

We currently have six municipalities with planned start-up during August and September. In addition, dialogues are ongoing with a further twelve municipalities where contract proposals are on the table and where the ambition is to start during Q3.

At the same time, several municipalities continue to conduct their own procurements alongside ADDA, which means that we continue to work in parallel across several different processes. Our view is that the market is now maturing rapidly. More municipalities have moved from wanting to understand what a medication dispenser is, to actively planning how Dosell can be introduced into their operations.

To meet the increased level of activity, we have continued to strengthen the organisation, including through the recruitment of a new implementation specialist with experience from close care and municipal operations. This strengthens our ability to carry out start-ups with high quality and create confidence among both staff and users.

The Netherlands – pipeline, structure and upcoming deliveries
In the Netherlands, we continue to build a stronger foundation for scaling. During the spring, we have strengthened the local organisation and introduced better structure for pipeline management, customer follow-up, planned rollouts and prioritisation of business opportunities.

We see very clear potential in the Dutch market. Several care organisations are in active dialogues regarding scaling, and the work is now focused on converting these opportunities into planned rollouts, active units and recurring revenue. The market places high demands on integrations, support and adapted implementation flows, which makes structure and the right prioritisation essential in order to scale effectively.

As previously communicated, manufacturing has been affected by delayed components. These are now expected to arrive in early July, which means that manufacturing can begin during the month. The objective is to start delivering new Dosell units from August to customers in the Netherlands that are awaiting the updated version, in line with each organisation’s readiness for rollout. This is an important piece of the puzzle in enabling us to scale up in the Netherlands during the second half of the year.

Other markets
In Norway, work continues together with existing and potential partners. We continue to see growing interest in medication dispensers and are working to create the right conditions for upcoming implementations.

In Finland, Iceland and Spain, work continues together with our partners. Although we do not have any major news to communicate from these markets this month, important dialogues and preparations are ongoing, strengthening our opportunities for the coming periods.

Product, operations and organisation
During June, we have continued to work on product improvements, integrations, onboarding and operational stability. As more customers and markets are added, this work becomes increasingly important. Our ambition is for Dosell to be easy to implement, safe to use and scalable for both small and large organisations.

We are also using the summer to strengthen our internal processes. This includes training materials, clearer customer journeys, better follow-up and improved structure in sales and implementation. This may not always be the most visible work externally, but it is critical to enabling us to grow faster and in a more controlled way during the autumn.

Summer break for the monthly letter
As July is normally a quieter period for many customers and partners, the monthly letter will now take a summer break. The next monthly letter will be published in September and will cover the month of August. As usual, we will communicate separately if any events occur that need to be disclosed in accordance with applicable regulations.

Looking ahead – focus on start-ups, delivery and autumn growth
We enter the summer with a stronger pipeline than before, both in Sweden and the Netherlands. At the same time, it is important to be clear that much of this pipeline now needs to be converted into actual implementation during the second half of the year.

Our priorities going forward are to:
• Carry out planned start-ups in Sweden during August and September
• Continue work with call-offs through ADDA
• Drive ongoing contract dialogues towards decisions
• Begin deliveries from the new production to the Netherlands
• Continue strengthening the organisation and our implementation processes
• Support our partners in other markets

We continue to work long-term and with clear focus to make Dosell a natural part of the future of medication management.

Thank you for following our journey. We wish you a great summer.